ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, ...

A compelling session at the EHA Congress explored how space research is reshaping our understanding of hematologic processes.

Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide.

GEO-CM04S1 Demonstrates Superior T Cell Responses Compared to mRNA Vaccine in Phase 2 Trial Among Immunocompromised Patients ...

CEPHEUS trial lead investigator Saad Z. Usmani, MD, MBA, FACP, FASCO, explains how the trial both builds on current knowledge of newly diagnosed multiple myeloma and how transplant-ineligible status ...

Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models ...

Experts reassess endpoints, patient selection, targets, and timing for the development of successful immune-based treatments ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the best stocks to buy for beginners now. On June 12, Bristol Myers Squibb ...

The lack of therapeutic precision in treatment of myeloid malignancies is in sharp contrast with the fact that myeloid cancers represent the perhaps best characterized cancers of all at the cellular, ...

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

conditions at the 30 th Annual Congress of the European Hematology Association (EHA) in Milan, Italy. "We are very proud to have sponsored this trial - the first of its kind - evaluating an oral agent ...